Advertisement
Orchard Therapeutics Says FDA Accepts BLA For OTL-200 In Metachromatic Leukodystrophy
(RTTNews) - Orchard Therapeutics (ORTX), a global gene therapy leader, announced Monday that the U.S. Food and Drug Administration (FDA) has accepted the filing of its Biologics License Application (BLA) for OTL-200 in metachromatic leukodystrophy (MLD) under Priority Review.
The BLA for OTL-200 is based on data from 39 pediatric patients with early-onset MLD, enrolled in two prospective non-randomized clinical studies or treated under expanded access frameworks, who were administered OTL-200 and compared with natural history data from 49 untreated patients.
In clinical trials, treatment with OTL-200 resulted in preservation of motor function and cognitive development in most patients compared to disease natural history with up to 12 years of follow-up.
The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of March 18, 2024.
OTL-200 would be the first and only treatment in the U.S. for early-onset MLD. The company said it is working diligently in parallel to prepare for a potential launch in 2024.
The previously published data demonstrated administration of one-time gene therapy enables sustained preservation of motor function and cognitive development.
OTL-200 previously received both Rare Pediatric Disease (RPD) and Regenerative Medicine Advanced Therapy (RMAT) designations from the FDA.
Orchard Therapeutics Gets Swissmedic Approval For Libmeldy In Early-onset MLD
Swiss Market Ends On Positive Note
European Stocks Close On Firm Note On Trade Deal Optimism, Earnings
TSX Modestly Higher On Positive Jobs Data, Earnings Updates
Bay Street Headed For Positive Start
FTSE Up Nearly 0.5% On Easing Tariff Concerns
CAC 40 Up 0.75% On Easing Trade Tensions
